First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial
Primary result · Total (first and subsequent) 3-P MACEResult — go to the resultMean ratio 0.86 95% CI 0.76–0.97Authors' conclusion
Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population.
Study context
- Population
- Participants with type 2 diabetes and atherosclerotic CV disease and/or chronic kidney diseaserandomized 1:1, median (IQR) follow-up 49.5 (44.0–54.9) months
- Participants
- 9,650 participants
- Comparison
- Oral semaglutide vs placebo
- Primary endpoint
- Total (first and subsequent) 3-P MACE
Methodological details444 centers in 33 countries
- 444 centers in 33 countries
Primary result
Total (first and subsequent) 3-P MACE
Mean ratio
0.86
95% CI 0.76–0.97
P = 0.01
Events by treatment group
Oral semaglutide
683 total; 579 first and 104 subsequent events
events
Placebo
791 total; 668 first and 123 subsequent events
events
As reported in the abstract
Further findings
Events events
| Outcome | Oral semaglutide | Placebo | Mean ratio (95% CI) | P value |
|---|---|---|---|---|
| Total 3-P MACE plus non-CV death | 910 | 1048 | 0.87 (0.79–0.95) | P = 0.004 |
- Total 3-P MACE plus non-CV death — Fewer total events with oral semaglutide
- 138
Safety
Adverse events leading to treatment discontinuation · As previously reported
Original publication
First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA Cardiol. Published 11 November 2026. doi:10. 1001/ jamacardio. 2026. 4944
Composed by AI from the published abstract and checked against it. How Briefs are made →